DR. FARID JALINOUS, M.D.

GOSHEN, IN

Research Active
Internal Medicine - Interventional Cardiology NPI registered 21+ years 1 publication 1997 – 1997 NPI: 1093717282
Internal Medicine - Interventional Cardiology Internal Medicine - Cardiovascular Disease

Practice Location

1855 S MAIN ST STE A
GOSHEN, IN 46526

Phone: (574) 533-7476

What does FARID JALINOUS research?

Dr. Jalinous studies how medications can improve outcomes for patients undergoing heart procedures, particularly focusing on a technique called directional coronary atherectomy. This involves removing blockages from heart arteries to improve blood flow. He examines the effects of medications like diltiazem, which can help prevent heart attacks and other serious issues during and after these procedures. His research aims to ensure that patients experience fewer complications, making heart treatments safer and more effective.

Key findings

  • Pretreatment with diltiazem reduced non-Q-wave heart attack rates from 6.8% to 2.7%.
  • The occurrence of abrupt closure of blood vessels decreased from 6.2% to 2.5% after diltiazem was administered.
  • These findings indicate a significant reduction in risk associated with directional coronary atherectomy when diltiazem is used.

Frequently asked questions

Does Dr. Jalinous study heart diseases?
Yes, he specifically researches how to improve safety during heart procedures.
What treatments has Dr. Jalinous researched?
He has studied the use of diltiazem as a pre-treatment medication to reduce complications during heart procedures.
Is Dr. Jalinous's work relevant to patients undergoing heart surgery?
Yes, his research directly benefits patients by aiming to make heart procedures safer and decrease the risk of complications.

Publications in plain English

Pretreatment with Intracoronary Diltiazem Reduces Non-Q-Wave Myocardial Infarction Following Directional Atherectomy.

1997

The Journal of invasive cardiology

Jalinous F, Mooney JA, Mooney MR

Plain English
This study looked at the effects of a medication called diltiazem given before a heart procedure known as directional coronary atherectomy (DCA). It found that patients who received diltiazem had a lower chance of experiencing non-Q-wave heart attacks, with rates dropping from 6.8% to 2.7%, and fewer cases of abrupt closure of blood vessels, falling from 6.2% to 2.5%. These results are important because they suggest that using diltiazem can make heart procedures safer. Who this helps: This benefits patients undergoing directional coronary atherectomy.

PubMed

Frequent Co-Authors

JA Mooney MR Mooney

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.